Clinical Trials Logo

Clinical Trial Summary

ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.

Clinical Trial Description

This is a phase 2a, prospective, open-label study. Primary objective of the study is to determine safety and tolerability profile of twice daily oral administration of ZYIL1 administered for 7 days. The study will be conducted in 3 subjects having CAPS as per eligibility criteria. The study will be divided in three periods: Screening Period; Run-in Period and Study Period. ;

Study Design

Related Conditions & MeSH terms

  • Cryopyrin Associated Periodic Syndrome
  • Cryopyrin-Associated Periodic Syndromes
  • Syndrome

NCT number NCT05186051
Study type Interventional
Source Cadila Healthcare Limited
Contact Dr Taufik Momin, MD
Phone 02717665555
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 17, 2022
Completion date November 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT04086602 - Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334 Phase 1
Recruiting NCT04856540 - Adult Outcomes of Children With CAPS
Completed NCT01105507 - The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Phase 3